Export status of raw material pharmaceutical products in China: Although the situation is improving | Obstacles still need to be cleared
Medical Network March 23th The pace of development in the domestic pharmaceutical industry is gradually accelerating. More and more pharmaceutical products are going out of the country and rushed to the world. In terms of pharmaceutical product exports, raw material medicine can be said to rise in volume and price. I learned that 2017 The annual export volume of raw material medicines reached 8.961 million tons, a record high, an increase of 8.33% year-on-year; the average export price has bottomed out, up 4.96% year-on-year, and the prices have recovered compared to the previous year.
The improvement of the export situation of APIs is inseparable from the contributions of pharmaceutical companies. Recently, Chinese medicine Health products Import and Export Chamber of Commerce issued 2017 raw material medicine exports enterprise Among the top 50 lists, among them, Shiyao Group, General Pharmaceutical Co., Ltd. (hereinafter referred to as 'Pulu Pharmaceutical') and Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter referred to as 'Huahai Pharmaceutical') have become the top three in the list.
With regard to the advantage of the 50 companies in the export of APIs, some experts summarized these reasons: External situation, corporate foundation, core technologies and products. In the external environment, environmental protection issues are a major obstacle for API companies, and the current situation of environmental protection supervision. Severely, the overcapacity situation of related products has changed, such as vitamins. The author understands that CSPC has an advantage in the export of APIs, and under the prevailing environmental protection, CSPC's vitamin products are getting good. It is reported that CSPC Group Vitamin C exports exceeded US$200 million for the first time, an increase of more than 50% year-on-year.
On the basis of the company, experts analyzed that many companies on the list have a solid basis for the production of APIs and use this advantage to extend them to other businesses, such as Pro-Pharma. It is reported that Pro-Pharma has a good foundation. In the active production of APIs will extend the tentacles to the formulation market.
In terms of core technologies and products, API companies have advantages that cannot be ignored. For example, Huahai Pharmaceutical, Shanghai Chuangnuo medicine Pharmaceutical Group, Federal Pharmaceutical International Holdings Co., Ltd., Zhejiang Pharmaceutical Co., Ltd., etc. They actively build core products and increase the research and development of production technology, occupying a large market share among API exporters. In this case, Even after strict supervision and anti-dumping investigations, the company still maintains its advantages.
The above factors allow API companies to release their advantages and also allow the export volume of domestic APIs to continue to increase. However, according to relevant data, there are 32 companies with over US$100 million worth of APIs and 107 US$50 million. However, for China's already 11,000 raw material drug exporters, the concentration of raw material drug exporters is still low.
In addition to the low concentration of API exporters, there are several major issues that need attention. First, overcapacity. The number of API companies is increasing, many companies are still building large-scale production bases, blindly expanding production capacity. This situation has eased in the near future, but the problem of overcapacity is still serious at this stage.
Second, international standards have been raised. China is a big country in the production of APIs. Products are exported to various countries. Each country has different standards for APIs. Therefore, Chinese APIs must meet the requirements of each country's market. Terms and conditions. For example, if some APIs want to enter the US market or the European market, then relevant documents and certificates are needed. The US needs DMF files and Europe needs COS certificates. Not only that, APIs also have to meet international GMP regulations. , Conforms to related pharmaceuticals Regulation The required documents, and these requirements will only be more stringent.
Thirdly, raw material drug products have weak conversion capabilities. Industry insiders say that the raw material drug products exported by China are still at the bottom of the value chain, and there is still a big gap between the current domestic API drug production technology and other countries. The author was informed that some European countries The company has already transformed its R&D and production of high-performance APIs and gradually seized the high-end API market. In this view, the transition process of local API companies is still difficult.
Overall, the export trend of APIs in China is getting better and better. The advantages of enterprises in terms of production technology, production scale, quality standards, etc. have become increasingly prominent and can meet the needs of different customers. However, the rapid development of foreign companies can not be ignored. In response to fierce competition, local companies must also optimize their production processes, promote green innovation, and increase their investment in technology. Talent Other measures to overcome technical barriers. In addition, companies must also accelerate structural upgrading, improve their competitive advantage, actively explore emerging markets, expand sales channels, and use more powerful capabilities to respond to external challenges.
